Abstract

PurposeThe purpose of this paper is to understand how women with a diagnosis of schizophrenia or bipolar disorder approach medication decision making in pregnancy.Design/methodology/approachThe study was co-produced by university academics and charity-based researchers. Semi-structured interviews were conducted by three peer researchers who have used anti-psychotic medication and were of child bearing age. Participants were women with children under five, who had taken anti-psychotic medication in the 12 months before pregnancy. In total, 12 women were recruited through social media and snowball techniques. Data were analyzed following a three-stage process.FindingsThe accounts highlighted decisional uncertainty, with medication decisions situated among multiple sources of influence from self and others. Women retained strong feelings of personal ownership for their decisions, whilst also seeking out clinical opinion and accepting they had constrained choices. Two styles of decision making emerged: shared and independent. Shared decision making involved open discussion, active permission seeking, negotiation and coercion. Independent women-led decision making was not always congruent with medical opinion, increasing pressure on women and impacting pregnancy experiences. A common sense self-regulation model explaining management of health threats resonated with women’s accounts.Practical implicationsWomen should be helped to manage decisional conflict and the emotional impact of decision making including long term feelings of guilt. Women experienced interactions with clinicians as lacking opportunities for enhanced support except in specialist perinatal services. This is an area that should be considered in staff training, supervision, appraisal and organization review.Originality/valueThis paper uses data collected in a co-produced research study including peer researchers.

Highlights

  • The UK Government is prioritizing maternal mental health (Department of Health, 2012a; Mental Health Taskforce, 2016), with the costs of perinatal mental ill-health estimated at £8.1bn for each annual birth cohort, or almost £10,000 per birth (Bauer et al, 2014)

  • This paper presents a co-produced analysis of women’s accounts of anti-psychotic medication decision making during pregnancy

  • Co-production in research recognizes the different expertise of individual team members in terms j j PAGE 70 MENTAL HEALTH REVIEW JOURNAL VOL. 24 NO. 2 2019 of data collection, project management, training and supervision, qualitative analysis and paper writing, and requires different approaches are undertaken to value and include available expertise, sharing power, building productive relationships (INVOLVE, 2018)

Read more

Summary

Introduction

The UK Government is prioritizing maternal mental health (Department of Health, 2012a; Mental Health Taskforce, 2016), with the costs of perinatal mental ill-health estimated at £8.1bn for each annual birth cohort, or almost £10,000 per birth (Bauer et al, 2014). The influence of fathers on child mental health is beginning to be recognized, including their active involvement in the perinatal period supporting mothers (Khan, 2017). This paper uses data from a qualitative interview study to explore how women managing schizophrenia or bipolar disorder make decisions about anti-psychotic medication use in pregnancy. There are no anti-psychotic medications with UK licensing authorization for women who are pregnant or breastfeeding (NICE, 2014). The challenges that mothers with mental health problems can experience, which include feelings of guilt, problems coping with health difficulties, fear over losing custody of children and stigma, can start in pregnancy (Diaz-Caneja and Johnson, 2004; Jones et al, 2014)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call